Shanghai-based biopharmaceutical company Curon has raised $150 million in Series A funding round.
The funding was raised from Temasek and Boyu Capital, 6 Dimensions Capital also participated in the funding round.
Curon said it would use the proceeds from the financing to accelerate its pipeline assets into pre-clinical and clinical phases as well as support it in expanding its current portfolio pipeline.
Curon Biopharma is incubated by 6 Dimensions Capital, a healthcare-focused investment firm established in 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures.